Entropy Neurodynamics Strengthens IP Portfolio with New US Patent Filing Backed by Strong IBS Clinical Results
Entropy Neurodynamics Limited (ASX: ENP) has filed a new US provisional patent application to advance its TRP-8803 program, reinforcing its intellectual property position in psychedelic-assisted therapies for gut-brain disorders. The filing is supported by Phase 2a clinical data in treatment-resistant irritable bowel syndrome, which demonstrated a 75% patient response rate—significantly higher than conventional therapies that typically deliver 17% to 44% outcomes. This development builds on the Company’s existing international and Australian patents, extending protection across both oral and intravenous psilocybin-based treatments through to 2042. The expanded patent framework enhances long-term exclusivity while supporting Entropy’s US-focused development and partnering strategy. With strong clinical validation and growing IP coverage, the Company is positioning TRP-8803 as a differentiated solution in a large, underserved market with significant commercial potential.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Entropy Neurodynamics Strengthens IP Portfolio with New US Patent Filing Backed by Strong IBS Clinical Results
Entropy Neurodynamics Limited (ASX: ENP) has filed a new US provisional patent application to advance its TRP-8803 program, reinforcing its intellectual property position in psychedelic-assisted therapies for gut-brain disorders. The filing is supported by Phase 2a clinical data in treatment-resistant irritable bowel syndrome, which demonstrated a 75% patient response rate—significantly higher than conventional therapies that typically deliver 17% to 44% outcomes. This development builds on the Company’s existing international and Australian patents, extending protection across both oral and intravenous psilocybin-based treatments through to 2042. The expanded patent framework enhances long-term exclusivity while supporting Entropy’s US-focused development and partnering strategy. With strong clinical validation and growing IP coverage, the Company is positioning TRP-8803 as a differentiated solution in a large, underserved market with significant commercial potential.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au